Cholestyramine induced hyperchloremic metabolic acidosis.
The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria. After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness. Examination revealed confusion, jaundice, signs of chronic liver disease, portal hypertension and hepatic encephalopathy. Laboratory investigations confirmed a metabolic acidosis (pH 7.15) and hyperchloremia. Multiple cultures failed to reveal sepsis and a urinary pH of 4.85 together with tests of renal acidification, excluded renal tubular acidosis. She received 600 mEq of sodium bicarbonate intravenously over 36 hours by which time her mentation, electrolytes and pH were normal. It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.
D000138:Acidosis / Q000139:chemically induced*; D000368:Aged; D002712:Chlorides / Q000097:blood*; D002792:Cholestyramine Resin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy; D011537:Pruritus / Q000188:drug therapy; D013148:Spironolactone / Q000627:therapeutic use
D002712:Chlorides; D002792:Cholestyramine Resin; D013148:Spironolactone